73 related articles for article (PubMed ID: 34548320)
1. Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis.
Pizzamiglio S; Ciniselli CM; Triulzi T; Gargiuli C; De Cecco L; de Azambuja E; Fumagalli D; Sotiriou C; Harbeck N; Izquierdo M; Nuciforo P; Huober J; Cappelletti V; Cinieri S; Piccart M; Daidone MG; Pruneri G; Colombo MP; Tagliabue E; Verderio P; Di Cosimo S
Clin Cancer Res; 2021 Dec; 27(23):6307-6313. PubMed ID: 34548320
[TBL] [Abstract][Full Text] [Related]
2. Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials.
Fernandez-Martinez A; Rediti M; Tang G; Pascual T; Hoadley KA; Venet D; Rashid NU; Spears PA; Islam MN; El-Abed S; Bliss J; Lambertini M; Di Cosimo S; Huobe J; Goerlitz D; Hu R; Lucas PC; Swain SM; Sotiriou C; Perou CM; Carey LA
JAMA Oncol; 2024 May; 10(5):603-611. PubMed ID: 38546612
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens.
Dai MS; Feng YH; Chen SW; Masuda N; Yau T; Chen ST; Lu YS; Yap YS; Ang PCS; Chu SC; Kwong A; Lee KS; Ow S; Kim SB; Lin J; Chung HC; Ngan R; Kok VC; Rau KM; Sangai T; Ng TY; Tseng LM; Bryce R; Bebchuk J; Chen MC; Hou MF
Breast Cancer Res Treat; 2021 Oct; 189(3):665-676. PubMed ID: 34553296
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17).
Fukada I; Ito Y; Kondo N; Ohtani S; Hattori M; Tokunaga E; Matsunami N; Mashino K; Kosaka T; Tanabe M; Yotsumoto D; Yamanouchi K; Sawaki M; Kashiwaba M; Kawabata H; Kuroi K; Morita S; Ohno S; Toi M; Masuda N
Breast Cancer Res Treat; 2021 Dec; 190(3):425-434. PubMed ID: 34554370
[TBL] [Abstract][Full Text] [Related]
5. Phase II Prospective Study of Trastuzumab in Combination with S-1 and Oxaliplatin (SOX100) Therapy for HER2-Positive Advanced Gastric Cancer.
Mori Y; Kataoka H; Ebi M; Adachi K; Yamaguchi Y; Hayashi N; Hirata Y; Sobue S; Ishihara R; Suzuki Y; Mizushima T; Inoue Y; Hasegawa I; Ono S; Hirano A; Kimura Y; Seno K; Ozeki K; Shimura T; Kubota E
J Gastrointest Cancer; 2022 Dec; 53(4):930-938. PubMed ID: 34550548
[TBL] [Abstract][Full Text] [Related]
6. Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer.
Keenan TE; Guerriero JL; Barroso-Sousa R; Li T; O'Meara T; Giobbie-Hurder A; Tayob N; Hu J; Severgnini M; Agudo J; Vaz-Luis I; Anderson L; Attaya V; Park J; Conway J; He MX; Reardon B; Shannon E; Wulf G; Spring LM; Jeselsohn R; Krop I; Lin NU; Partridge A; Winer EP; Mittendorf EA; Liu D; Van Allen EM; Tolaney SM
Nat Commun; 2021 Sep; 12(1):5563. PubMed ID: 34548479
[TBL] [Abstract][Full Text] [Related]
7. Toxicity Index, Patient-Reported Outcomes, and Early Discontinuation of Endocrine Therapy for Breast Cancer Risk Reduction in NRG Oncology/NSABP B-35.
Henry NL; Kim S; Hays RD; Diniz MA; Luu M; Cecchini RS; Yothers G; Rogatko A; Ganz PA
J Clin Oncol; 2021 Dec; 39(34):3800-3812. PubMed ID: 34554865
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
Felip E; Altorki N; Zhou C; Csőszi T; Vynnychenko I; Goloborodko O; Luft A; Akopov A; Martinez-Marti A; Kenmotsu H; Chen YM; Chella A; Sugawara S; Voong D; Wu F; Yi J; Deng Y; McCleland M; Bennett E; Gitlitz B; Wakelee H;
Lancet; 2021 Oct; 398(10308):1344-1357. PubMed ID: 34555333
[TBL] [Abstract][Full Text] [Related]
9. Are Platinum Drugs Ineffective for Triple-Negative Breast Cancer With Residual Invasive Disease After Neoadjuvant Chemotherapy?
Shimanuki Y; Shimomura A; Yoshimura K; Terakado H; Shimizu C
J Clin Oncol; 2021 Nov; 39(31):3521-3522. PubMed ID: 34554850
[No Abstract] [Full Text] [Related]
10. Lack of cross-resistance between non-steroidal and steroidal aromatase inhibitors in breast cancer patients: the potential role of the adipokine leptin.
Bahrami N; Jabeen S; Tahiri A; Sauer T; Ødegård HP; Geisler SB; Gravdehaug B; Reitsma LC; Selsås K; Kristensen V; Geisler J
Breast Cancer Res Treat; 2021 Dec; 190(3):435-449. PubMed ID: 34554372
[TBL] [Abstract][Full Text] [Related]
11. Breast Cancer,
Bose R; Ma CX
N Engl J Med; 2021 Sep; 385(13):1241-1243. PubMed ID: 34551235
[No Abstract] [Full Text] [Related]
12. Poziotinib for Patients With
Elamin YY; Robichaux JP; Carter BW; Altan M; Gibbons DL; Fossella FV; Lam VK; Patel AB; Negrao MV; Le X; Mott FE; Zhang J; Feng L; Blumenschein G; Tsao AS; Heymach JV
J Clin Oncol; 2022 Mar; 40(7):702-709. PubMed ID: 34550757
[TBL] [Abstract][Full Text] [Related]
13. Real-World Analysis of the Efficacy and Safety of a Novel Irreversible HER2 Tyrosine Kinase Inhibitor Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer.
Sun Y; Chen B; Li J; Peng L; Li S; Yu X; Li L
Cancer Manag Res; 2021; 13():7165-7174. PubMed ID: 34548820
[TBL] [Abstract][Full Text] [Related]
14. Determinants of use of oral complementary-alternative medicine among women with early breast cancer: a focus on cancer-related fatigue.
Lapidari P; Djehal N; Havas J; Gbenou A; Martin E; Charles C; Dauchy S; Pistilli B; Cadeau C; Bertaut A; Everhard S; Martin AL; Coutant C; Cottu P; Menvielle G; Dumas A; Andre F; Michiels S; Vaz-Luis I; Di Meglio A
Breast Cancer Res Treat; 2021 Dec; 190(3):517-529. PubMed ID: 34559354
[TBL] [Abstract][Full Text] [Related]
15. Critical Appraisal of Adjuvant Platinum-Based Chemotherapy for Basal Subtype Triple-Negative Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy.
Shimoi T; Noguchi E; Sudo K; Chua YJ; Yonemori K
J Clin Oncol; 2021 Nov; 39(31):3519-3521. PubMed ID: 34554822
[No Abstract] [Full Text] [Related]
16. Efficacy and Prognosis of First-Line EGFR-Tyrosine Kinase Inhibitor Treatment in Older Adults Including Poor Performance Status Patients with
Chang CY; Chen CY; Chang SC; Lai YC; Wei YF
Cancer Manag Res; 2021; 13():7187-7201. PubMed ID: 34552354
[TBL] [Abstract][Full Text] [Related]
17. Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring
Meric-Bernstam F; Bahleda R; Hierro C; Sanson M; Bridgewater J; Arkenau HT; Tran B; Kelley RK; Park JO; Javle M; He Y; Benhadji KA; Goyal L
Cancer Discov; 2022 Feb; 12(2):402-415. PubMed ID: 34551969
[TBL] [Abstract][Full Text] [Related]
18. FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer.
Gombos A; Venet D; Ameye L; Vuylsteke P; Neven P; Richard V; Duhoux FP; Laes JF; Rothe F; Sotiriou C; Paesmans M; Awada A; Guiot T; Flamen P; Piccart-Gebhart M; Ignatiadis M; Gebhart G
NPJ Breast Cancer; 2021 Sep; 7(1):125. PubMed ID: 34548493
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer.
Vos H; Lambein K; Richard F; Mariën B; Nevelsteen I; Punie K; Wildiers H; Berben L; Laenen A; Floris G; Desmedt C; Smeets A
NPJ Breast Cancer; 2021 Sep; 7(1):128. PubMed ID: 34556657
[TBL] [Abstract][Full Text] [Related]
20. Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non-Hodgkin Lymphoma.
Ribeiro ML; Reyes-Garau D; Vinyoles M; Profitós Pelejà N; Santos JC; Armengol M; Fernández-Serrano M; Sedó Mor A; Bech-Serra JJ; Blecua P; Musulen E; De La Torre C; Miskin H; Esteller M; Bosch F; Menéndez P; Normant E; Roué G
Clin Cancer Res; 2021 Dec; 27(23):6591-6601. PubMed ID: 34551904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
